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Circulating CD11c+ B cells are a key phenomenon in certain types of autoimmunity but
have also been described in the context of regular immune responses (i.e., infections,
vaccination). Using mass cytometry to profile 46 different markers on individual immune
cells, we systematically initially confirmed the presence of increased CD11c+ B cells in
the blood of systemic lupus erythematosus (SLE) patients. Notably, significant differences
in the expression of CD21, CD27, and CD38 became apparent between CD11c− and
CD11c+ B cells. We observed direct correlation of the frequency of CD21−CD27− B
cells and CD21−CD38− B cells with CD11c+ B cells, which were most pronounced
in SLE compared to primary Sjögren’s syndrome patients (pSS) and healthy donors
(HD). Thus, CD11c+ B cells resided mainly within memory subsets and were enriched
in CD27−IgD−, CD21−CD27−, and CD21−CD38− B cell phenotypes. CD11c+ B cells
from all donor groups (SLE, pSS, and HD) showed enhanced CD69, Ki-67, CD45RO,
CD45RA, and CD19 expression, whereas the membrane expression of CXCR5 and
CD21 were diminished. Notably, SLE CD11c+ B cells showed enhanced expression of
the checkpoint molecules CD86, PD1, PDL1, CD137, VISTA, and CTLA-4 compared to
HD. The substantial increase of CD11c+ B cells with a CD21− phenotype co-expressing
distinct activation and checkpoint markers, points to a quantitative increased alternate
(extrafollicular) B cell activation route possibly related to abnormal immune regulation as
seen under the striking inflammatory conditions of SLE which shows a characteristic
PD-1/PD-L1 upregulation.
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INTRODUCTION
B cells play a key role in adaptive immunity through their
ability to produce antibodies and through several antibody-
independent functions such as antigen-presentation and immune
regulation. In chronic autoimmune diseases, such as systemic
lupus erythematosus (SLE) and primary Sjögren’s syndrome
(pSS), a variety of B cell disturbances have been described, among
them, increased CD11c+ B cells (1–3). This population, which
is not uniformly defined yet (4), has been proposed to be a
source of autoreactivity in autoimmune diseases (1). In mice
CD11c expression in B cells is promoted by IFN-γ and IL-21 and
antagonized by IL-4 in TLR7 and TLR9 stimulated B cells (5). In
healthy donors (HD), it has been reported that CD11c+ B cells in
blood display amemory phenotype (6). The current conventional
definition of human circulating memory B cells is based on CD27
and IgD expression to assign memory B cells to CD27+IgD+,
CD27+IgD− and CD27−IgD− (“double negative,” DN) subsets.
As a further marker CD21 has been suggested to reflect the
activation status of memory B cells. CD21 is downregulated in
conditions of chronic immune stimulation, e.g., autoimmune
diseases like SLE (7) and rheumatoid arthritis (8), in primary
immunodeficiency associated with immune dysregulation (9),
infections like HIV (10) and malaria (11), among others.
In this study, we applied a comprehensive integrated
phenotyping using 46 different markers to study CD11c+ B
cells in healthy donors, pSS and SLE patients in order to
identify disease-related quantitative and qualitative differences
of this cellular subset. As a result, we found that CD11c+
B cells are in their majority CD21− and belong to the
memory compartment. CD11c+ B cells display a distinct
phenotype with an increased expression of activation and
checkpoint inhibitory markers. In autoimmune patients and in
particular in SLE, CD11c+ B cells were characteristically enriched
among CD27−IgD−, CD27−CD21− as well as CD21−CD38−
compartments, alongside with increased expression of some
activation and checkpoint inhibitory markers compared to HD
in particular in SLE followed by pSS. These findings point
to circulating CD11c+ CD21low B cells, which abundance is
increased in the blood of SLE and pSS patients, as disease-related
peripheral B cells, likely generated in extrafollicular immune
reactions and escaping physiological immune regulation.
MATERIALS AND METHODS
Study Participants
Blood was drawn from 18 healthy donors (HD), 27 SLE
patients and 22 pSS patients in Lithium Heparin (LiHep)-
anticoagulated and EDTA-anticoagulated tubes (Greiner Bio-
One). Detailed information on patient demographics as well
as clinical and serological parameters are summarized in
Supplementary Tables 1–3. The study has been approved by
the local ethics committee of Charité Universitätsmedizin
Berlin and written consent was obtained from all patients and
healthy donors.
Whole Blood Stainings of Major Subsets
and CD169/SIGLEC-1
Absolute numbers of T, B, and NK cells were assessed with
BD Multitest 6-color TBNK according to the manufacturer’s
instructions (BD Biosciences) using a BD FACS Canto II flow
cytometer. Lysis of EDTA-anti-coagulated blood and staining
for CD169/SIGLEC-1 expression on CD14+ monocytes was
performed as described (12, 13).
Isolation and Storage of Mononuclear Cells
Peripheral blood mononuclear cells (PBMCs) were isolated
from Li-Hep-anticoagulated blood as described previously (14).
Briefly, blood was mixed with PBS (Biochrom) and subjected
to density gradient centrifugation with Ficoll Paque Plus (GE
Healthcare). Collected mononuclear cells were washed twice
with PBS and counted for further experiments. For subsequent
stainings, up to 10 × 106 PBMCs were transferred to FBS/10%
DMSO, frozen to −80◦C in a CoolCell Cell Freezing Container
(Biocision) and stored at−80◦C until further processing.
Staining and CyTOF Acquisition
A total of 2 × 106 PBMCs per sample were plated into 96-
well v bottom plates and washed with PBS (Fluidigm). Cells
were resuspended in 100 µL cisplatin solution (1:2,500 in
PBS; Fluidigm) and incubated for 3min at room temperature.
Fifty microliters cell staining buffer (CSB; Fluidigm) was added
to quench residual Cisplatin. Cells were washed twice with
CSB and fixed with Fix I buffer (1:5 in PBS; Fluidigm) for
10min at room temperature. Cells were washed with CSB and
incubated in 100µL Barcode/Perm buffer (1:10 in PBS; Fluidigm)
supplemented with 2 µL of barcoding reagent (Fluidigm) for
10min at room temperature. Subsequently, cells were washed
with Barcode/Perm buffer and with CSB and pooled in a
1.5mL low protein binding conical tube (Eppendorf). Twenty
microliters of Fc-blocking reagent (130-059-901;Miltenyi Biotec)
was added to the cell pellet. For each duplicated, cells were
resuspended in 300 µL of one of the staining cocktails in PBS
(Supplementary Table 4) and incubated for 30min at room
temperature. Overall, 46 markers could be analyzed in two
stainings with a common backbone of 22 markers. Thereafter,
cells were washed twice with CSB, resuspended in 500 µL
permeabilization buffer (1:10 in water; 00-8333-56; eBioscience)
and incubated for 30min at 4◦C. To block unspecific binding
of antibodies to intracellular targets, cells were blocked with
1% normal rabbit serum (31883) and 1% normal mouse serum
(31880; both Invitrogen) in permeabilization buffer for 15min at
4◦C. Antibodies were added in a total volume of 300 µL in the
presence of 1% rabbit serum and 1%mouse serum and incubated
for 60min at 4◦C. Cells were washed twice with permeabilization
buffer and once with CSB prior to overnight storage in 1mL
intercalator solution (1:6,000 in Perm/Fix buffer; Fluidigm). The
next day, cells were washed three times with CSB and twice with
water to remove any residual protein. Cell count was determined
and cells were diluted with water to a final concentration of 7
× 105 cells/mL. Prior to acquisition, cells were filtered through
a 35µm cell strainer (352235, Corning) and calibration beads
(201078, Fluidigm) were added at a 1:10 ratio (v/v). A Helios
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mass cytometry instrument (Fluidigm) was used for sample
acquisition. Data analysis was performed using the Cytobank
platform. The data were obtained and analyzed according to the
“Guidelines for the use of flow cytometry and cell sorting in
immunological studies” (15).
Data Analysis and Statistics
Flow cytometry data were analyzed using FACSDiva software
(Becton Dickinson) and FlowJo (version 10.6.1, TreeStar). For
the presentation of t-SNE plots, a concatenated file composed of
22.500 B cell from 15 HD, 15 pSS, and 15 SLE (500 downsampled
B cells per donor) with staining panel B was used to ensure
robust comparison of data into both the subsets and the cohorts.
Statistical analyses and graphical presentations were carried out
by using GraphPad Prism Software (GraphPad). For multiple
group comparison two-way ANOVA with Šidák’s post-test for
multiple comparison was used. Spearman correlation coefficient
was calculated to detect possible associations between parameters
or with disease activity. P-values were considered significant
when <0.05. Correlation matrix was calculated using base R and
corrplot package (R Foundation for Statistical Computing) using
Kendall method. Only correlations with p ≤ 0.01 were plotted in
the matrix.
RESULTS
Higher Frequency of CD11c+ B Cells in SLE
To address the frequency, distribution, and phenotype of
peripheral CD11c+ B cells, this study comprehensively analyzed
these characteristics among peripheral blood cells from 18
healthy donors, 22 pSS patients and 27 SLE patients by
mass cytometry, for the expression of overall 46 cell surface
proteins. Gating of CD11c+ B cells is shown in Figure 1A.
The frequency of CD11c+ B cells was significantly increased
in SLE patients compared to HD (p < 0.01; Figure 1B).
This observation validated that the population of interest is
increased in SLE, consistent with conventional flow cytometry
data (1). Interestingly, two-dimension t-SNE plots clustering
all peripheral B cells according to expression patterns of the
parameters analyzed (Figure 1C), showed a similar qualitative
distribution of CD11c+ B cells among the two patient groups
and healthy controls. However, CD11c+ B cells were slightly
increased in pSS (535 events) and showed a significant
enrichment in SLE patients (822 events), as compared to HD (408
events) (Figure 1C) when normalized to an acquisition of 7,500
B cells concatenated from 15 randomly selected individuals of
each group.
Circulating CD11c+ B Cells Lacking CD21
and CD27 Expression Are Enhanced in SLE
and pSS Patients
Initial analyses addressed the frequency of CD11c+ B cells
among certain B cell subsets classified into plasmablast
(CD27+CD38+), transitional (CD24+CD38+) and mature
populations (Figure 2A). Mature B cells were divided according
to CD27 and IgD into CD27−IgD+, CD27+IgD+, CD27+IgD−
and double negative (DN) CD27−IgD− subsets (Figure 2A); or
related to their CD21 and CD27 expression into CD21+CD27−,
CD21+CD27−, CD21−CD27+, and CD21−CD27− B cells
(Figure 2A).
To evaluate the relationship between CD11c+ B cells,
plasmablasts, transitional and mature B cells (the latter
classified according to IgD/CD27 and CD21/CD27 expression),
a correlation matrix was obtained from the three cohorts
(Figure 2B). Of interest, a significant positive correlation
between the frequencies of CD21−CD27− and those of CD11c+
B cells was observed for all patient groups as well as HD.
Interestingly, there was also a correlation between the frequencies
CD11c+ B cells with CD27−IgD− as well as CD27−CD38− B
cells for pSS and SLE patients, respectively, but not for HD
(Figure 2B).
Further analyses revealed a correlation between the
frequencies of CD11c+ and CD21−CD27− B cells both
from HD (r = 0.74, p = 0.0002), pSS (r = 0.60, p = 0.0013) and
SLE patients (r = 0.80, p < 0.0001) (Figure 2C). In addition,
frequencies of CD21−CD38− B cells closely correlated with
those of CD11c+ B cells from all three cohorts (Figure 2C, see
next section). No correlation was found for the frequencies
of CD11c+ B cells and the age of the individual donors, the
expression of Siglec-1 (CD169) on monocytes (as marker of the
type I interferon signature) or the disease activity scores SLEDAI
for SLE and ESSDAI for pSS, respectively (data not shown).
Thus, the data indicate that CD11c+ B cells are more intimately
related but not restricted to atypical memory B cells lacking
CD21 and/or CD38 expression prompting additional studies.
CD11c+ B Cells Are Characteristically
Enriched Within the Atypical B Cells
Lacking Expression of CD21 and CD38
Plasmablasts (CD38+CD27+), transitional (CD38highCD24high)
and CD21+CD27− B cells showed lower frequency of CD11c+
B cells than the overall B cell population. The remaining
three populations exhibited higher frequencies of CD11c+ cells
(Figure 3A) that were even higher than among CD27−IgD− B
cells (Supplementary Figure 1A). Thus, the majority of CD11c+
B cells carried a mature phenotype (>80%). Frequencies of
plasmablasts and transitional subsets among CD11c+ and global
B cell population were similar, with no differences between the
study groups (Figure 3B).
Subsequently, mature B cells and CD11c+ mature B cells
were classified according to their expression of CD27 and
IgD (Figure 2A). In general, frequencies of CD11c+ B cells
were enhanced among all memory B cell subsets across
all cohorts, and low among CD27−IgD+ naïve B cells
(Supplementary Figure 1A). Interestingly, differences between
SLE and pSS patients and HD were found for the three
memory subsets (CD27+IgD+; CD27+IgD− and CD27−IgD−).
In particular, an increased frequency of CD11c+ B cells carrying
a DN (CD27−IgD−) phenotype in SLE compared to pSS
(p < 0.01) and HD (p < 0.0001) was observed, while lower
frequencies of CD11c+ B cells with CD27+IgD+ (pSS and SLE
vs. HD) and CD27+IgD− (SLE vs. pSS and HD) were identified
(Supplementary Figure 1C). Comparison of t-SNE distribution
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FIGURE 1 | Increased CD11c+ B cells in SLE patients. (A) Representative pseudocolor plots of B cells (left) and CD11c+ B cells (right) from a control (HD). (B)
Median of frequency of CD11c+ B cells from 18 HD, 22 pSS and 27 SLE patients, each point represents a donor. Kruskal-Wallis test with Dunn’s post-test. **p <
0.01. (C) t-SNE plots of CD11c+ B cells (Blue) and general B cell (gray) populations. t-SNE was performed from concatenated file composed from 15 HD, 15 pSS and
15 SLE (7,500 events per group). Number of events of CD11c+ and B cells are indicated for each t-SNE plot.
supported the enrichment of CD11c+ B cells among memory
subsets, but especially within CD27−IgD− B cells in SLE patients
(Supplementary Figure 1C).
CD21 has been described to be related to CD11c expression
linked to B cell activation, autoimmunity and as part of
age associated B cells phenotype (16–19). A classification
of B cells according to their CD21 and CD38 expression in
CD21+, CD21−CD38− and CD21−CD38+ further revealed the
characteristics of CD11c+ B cells (Supplementary Figure 2A).
While CD11c+ B cells were substantially lower among
CD21+ B cells, with marked differences between the cohorts
(Supplementary Figure 2B), there was a remarkable enrichment
of CD11c+ B cells among CD21−CD38− B cells. Frequencies of
CD21−CD38− B cells showed a weak correlation with those
of CD11c+ B cells in HD (r = 0.47, p = 0.024), but strong
correlations in pSS (r = 0.82, p = 0.0001) and SLE (r = 0.84, p
< 0.0001), respectively (Figure 2C). This observation suggests a
potential role for the phenotype of CD21−CD38− B cells during
pronounced immune activation as seen in SLE and to a lesser
extent for pSS in contrast to controls.
The frequencies of CD11c+ B cells expressing either CD21
and those which were negative for CD21 and CD38 were
similar in HD (Supplementary Figure 2B). CD11c+ B cells
appeared to be enriched in particular among CD21−CD27+
and CD21−CD27− B cells, compared to the overall B cell
population (Figure 3A). Compared to the overall B cell
population, CD11c+ B cells resided largely among CD21−
subsets (CD21−CD27+and CD21−CD27−) in all three cohorts.
Of particular note, frequencies of CD11c+ B cells carrying the
CD21−CD27− phenotype were increased in SLE compared to
HD (p < 0.001) and pSS (p < 0.01) (Figure 3C). Comparison
of t-SNE distribution of general mature B cells and the
CD11c+ mature B cell population among CD21+CD27−,
CD21+CD27+, CD21−CD27+, and CD21−CD27− populations
of the cohorts is shown in Figure 3D. Here, the characteristic
enrichment of CD11c+ B cells among CD21−CD27− B cells
and within CD21−CD38− B cells (Supplementary Figure 2C)
as characteristics of these cells in SLE became clearly evident
(Figure 3D).
CD11c+ B Cells Express Checkpoint
Molecules Carry - Increased PD-1 and
PD-L1 Mark CD11c+ B Cells in SLE
A particular goal of this study was to identify the checkpoint
molecule expression profile by CD11c+ B cells in autoimmunity.
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FIGURE 2 | Subset characterization of CD11c+ B cells. (A) Representative pseudocolor plots of gating of CD19+ B cells into plasmablasts (left), transitional and
mature B cells (middle left), and representative pseudocolor plots of IgD/CD27 based classification (middle right) and CD21/CD27 based classification of mature B
cells (left) from a HD. (B) Kendall correlation matrix showing the correlation of frequency of each B cell subset (as shown in A) together with CD11c+ B cells from 18
HD (left), 22 pSS (center), and 27 SLE (right). Correlations are represented by red (negative) or blue (positive) circles, referring the size and intensity of color to the
strength of correlation. Only correlations with p ≤ 0.01 are indicated. (C) Spearman rank correlation between CD11c+ with CD21−CD27− (upper left), CD21−CD38−
(lower panel left) and CD27− IgD− (upper panel right) populations from 18 HD, 22 pSS, and 27 SLE, respectively. Each point represents a donor.
As a result, CD11c+ B cells showed a higher activation status
as compared to CD11c− B cells, with increased expression of
CD69 (p < 0.001) and CD86 (p < 0.001) across all three
groups of donors (Figure 4A). CD69 expression of SLE B
cells (p < 0.05) and CD86 expression of B cells from pSS
(p < 0.05) and SLE patients (p < 0.05) were significantly
increased for CD11c+ B cells compared to HD (Figure 4A).
CD11c+ B cells from pSS (p < 0.05) and SLE patients
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FIGURE 3 | Increased frequency of CD11c+ B cells carrying CD21−CD27− phenotype in SLE patients. (A) Representative pseudocolor plots of CD11c expression by
B cell subsets (in CD19+ B cells, plasmablasts, transitional B cells, CD21+CD27−, CD21+CD27+, CD21−CD27+, and CD21−CD27− populations from left to right)
from a HD. (B) Median of frequency of plasmablasts, transitional B cells and mature B cells in overall B cells and CD11c+ B cells from 18 HD, 22 pSS and 27 SLE
patients, each point represents a donor. Two way ANOVA with Šidák’s post-test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. (C) Median frequency of
CD21/CD27 based phenotypes in mature B cells and CD11c+ mature B cells from 18 HD, 22 pSS and 27 SLE patients, each point represents a donor. Two-way
ANOVA with Šidák’s post-test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. (D) t-SNE plots of CD21+CD27−, CD21+CD27+, CD21−CD27+, and
CD21−CD27− populations in general B cells (upper panel) and CD11c+ B cells (lower panel) from HD (left), pSS (middle) and SLE (right) patients. t-SNE was
performed from concatenated files composed from 15 HD, 15 pSS and 15 SLE (7,500 events per group), respectively. The number of events of each subset in B cells
and CD11c+ cells are indicated for each t-SNE plot.
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FIGURE 4 | Distinct expression pattern by CD11c+ B cells. Median signal intensity of (A) Activation and proliferation markers (CD69, CD86, Ki67, and CXCR5), (B)
Checkpoint molecule expression (PD1, PDL1, CD137, CTLA4, CDD226, ICOS, and VISTA) among CD11c− and CD11c+ from 18 HD, 22 pSS and 27 SLE patients,
each point represents a donor. Two-way ANOVA with Šidák’s post-test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
(p < 0.0001) also showed a higher Ki67 expression, when
compared to HD (Figure 4A). Moreover, CD11c+ B cells showed
diminished expression of CXCR5 (p < 0.0001) in all groups
compared to CD11c− B cells, suggesting their routing outside
of germinal centers. Although a remarkably lower CXCR5
expression has been observed in CD11c− B cells from SLE
patients compared to HD (p < 0.0001) and pSS (p < 0.05)
patients, respectively, this alteration was not observed among
CD11c+ B cells (Figure 4A).
A characteristically higher expression of CD45RO (p < 0.001)
and CD19 (p < 0.01) together with a lower expression of
CD38 (p < 0.01) by CD11c+ B cells from all three groups
was detected (Supplementary Figure 3). Furthermore, a higher
expression of CD45RA (p < 0.01) among CD11c+ B cells from
HD and pSS but not SLE was found (Supplementary Figure 3).
In addition, CD45RA expression was lower on CD11c+ B
cells from SLE compared to HD (Supplementary Figure 3).
No differences in IgA, IgG, and IgM expression between
CD11c+ and CD11c− or between study groups were found
(Supplementary Figure 3).
Analysis of the expression of certain checkpoint inhibitors
revealed that CD11c+ B cells had a significantly increased
expression of PDL1 (p < 0.0001), CD137 (4-1BB, p < 0.001),
VISTA (p < 0.05) and CTLA4 (p < 0.05), as compared to
CD11c− B cells (Figure 4B). No striking differences were found
for BTLA and PSGL-1 between CD11c+ and CD11c− B cells
and between groups of patients (Supplementary Figure 3). One
notable difference in terms of checkpoint inhibitor expression
was the increased PD1 expression on CD11c+ B cells in
SLE compared to CD11c− (p < 0.0001) and compared to
CD11c+ B cells from HD (p < 0.0001) and pSS (p <
0.001) patients (Figure 4B). An increased PDL1 expression
was observed among CD11c+ B cells for pSS (p < 0.01)
and SLE (p < 0.0001) compared to controls (Figure 4B).
Overall, enhanced expression of a distinct pattern of checkpoint
molecules (PDL1, CD137, CTLA4, CD226, ICOS, and VISTA)
was a characteristic of CD11c+ B cells, across all groups
studied (Figure 4B). There were no differences in data of
patients classified according to disease activity score, medication
and organ involvement (Supplementary Figure 4 and data
not shown).
In summary, CD11c+ B cells are enhanced among
memory B cell subsets with reduced CD21 and CD38
expression, and a characteristic profile of CD69, CD86,
PDL1, CD137, and CTLA4 expression. Substantially increased
PD1 together with elevated PD-L1expression on CD11c+ B
cells was found as a characteristic and unique finding of SLE
CD11c+ B cells.
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DISCUSSION
Although CD11c+ B cells have been suggested as a key player
in autoimmunity, a comprehensive analysis of them including
detailed studies of their checkpoint molecule expression between
different autoimmune conditions had not been undertaken
so far. In this study we have used mass cytometry-based
immunophenotyping to that end. We observed an increased
frequency of CD11c+, mostly CD21− B cells among all
circulating B cells of SLE patients. CD11c+ B cells of SLE and
pSS patients showed a number of phenotypic differences. In the
literature the terms of CD11c+ and CD11chigh are often not
sharply separated while it is important to note that CD11chigh B
cells are only a fraction of total CD11c+ B cells. Both populations
have been described to be increased in SLE patients (1), but also
under physiological conditions of immune challenges, such as
infections and in response to vaccinations (20).
CD11c+ circulating B cells are enriched among
CD21+CD27+, CD21−CD27+ and especially CD21−CD27−
B cells, as compared to all B cells. A striking correlation of
CD11c+ and CD21−CD27− expression was observed for B
cells of all the three study groups, but was especially enriched
in SLE. A significant correlation was found for CD11c+ and
CD21−CD38− B cells in SLE and pSS patients, while the
correlation was less among controls. Circulating CD21− or
CD21low B cells have been described to be increased in frequency
in various autoimmune diseases like SLE (21), rheumatoid
arthritis (17) and pSS (22), as well in other conditions, like
malaria (11), COVID19 (23), CVID (19), chronic graft-versus-
host disease (24) hepatitis C (25) and in HIV infection (15),
reflecting chronic activation of the immune system. A common
denominator among these conditions is the continued egress of
activated B cells into the blood. In this context, reduced CXCR5
expression can be considered as another marker of recent
activation and/or B cell differentiation outside the conventional
GC differentiation route (26). It has been reported for mice, that
CD11c+ cells are located at the border of T cell to B cell zones in
the spleen (27). The reduced expression of CXCR5 by CD11c+
B cells described here, argues in favor of the extrafollicular
generation of CD11c+ B cells in autoimmunity, especially in
active disease, and the enrichment of autoreactive clones due
to the lack of proper selection outside germinal centers. It is
important to note that CD11c+ B cells were enriched among,
but not limited to CD21−B cells. The data are consistent with
a quantitative increase of atypical memory B cells carrying
the phenotype of CD11c lacking the expression of CD21
and CD38 which are possibly induced outside the GCs with
impaired selection under the condition of SLE followed by pSS
and HD.
CD21 expression of CD11c+ B cells was markedly diminished
in all studied donor groups, but most significantly among SLE
patients. CD11c+ B cells were mainly enriched, but not limited,
to the memory B cell phenotypes CD27+IgD+, CD27+IgD−,
and CD27−IgD−(DN), as previously reported (6), indicating
that CD11c+ expression is induced by B cell activation. An
increased frequency of DN B cells is a hallmark of SLE (7,
28, 29) and has also been described in rheumatoid arthritis
(30) and multiple sclerosis (31). Increased frequency of CD11c+
among the CD27−IgD− phenotype in SLE patients could
be explained by a combination of enrichment of CD11c+
cells (observed in both HD and patients) as well as the
increased DN phenotype in total B cells in SLE patients. It
is worth noting, that DN CD11c+ B cells are more frequent
among memory B cell subsets in SLE, as compared to pSS
and HD. The differences in the expression of markers in
CD11c+ compared to CD11c− B cells, showed most pronounced
changes in SLE B cells and to a lesser extent among pSS
patients. The data suggest that the mechanisms involved in
the generation of CD11c+ B cells are common across all
cohorts but their amplification in SLE and pSS appear to gain
pathogenic importance.
A key objective of the study was the characterization of
checkpoint molecule expression in connection to other markers
by CD11c+ B cells to gain additional insights. Here, an increased
expression of activation (CD69, CD86), proliferation (Ki67), pro-
survival (CD137) and co-inhibitory (PD1, PDL1) markers was
found. In addition, enhanced expression of CTLA4, CD226,
ICOS, and VISTA was found as a characteristic of CD11c+ B cells
across all groups studied. These markers together with reduced
CD21 are known to be induced upon B cell stimulation (32–35),
suggesting that CD11c+ are antigen-experienced and recently
activated cells. In addition to increased expression of CD69 and
CD86, SLE CD11c+ B cells carried a characteristically increased
PD1 and PD-L1 expression, suggesting that they result from
a dysregulation in SLE. After B cell stimulation an increased
expression of CD86, PD1 and PDL1 in B cells from HD and
SLE patients has been reported (33) supporting the idea that
CD11c+ B cells had previously been stimulated in vivo and their
generation is promoted in autoimmune conditions. CD11c+ B
cells of pSS patients also showed increased CD86 and PDL1 and
reduced CD27 expression, displaying a similar B cell disturbance
but less severe than SLE patients. Previous studies had shown
increased CD86 expression by all subsets of peripheral B cells
(36), while others described an increase in CD27+IgD− and DN,
but not in naïve or CD27+IgD+ B cell from pSS (37). Increased
PDL1 had been detected in salivary glands of pSS patients (38)
while data on PDL1 expression on pSS B cells are missing. It
remains to be further delineated whether these findings result
from their more extensive generation in SLE or really reflect a
unique abnormality in lupus.
In autoimmune diseases and infections, excessive activation
of B cells leads to an accumulation of exhausted/post-activated
peripheral B cells, characterized by hyporesponsiveness to
activating stimuli and upregulated expression of regulatory
markers, like PD1 and PDL1 (25, 39, 40). CD21 and CD11c
both have been described to play a role on chronic cognate
activation of B cells, and they are linked in several ways:
Transcripts of ITGAX, encoding CD11c, are upregulated in
CD21− B cells, which qualify as memory B cells due to their
class switched BCRs (16), or as anergic B cells due to their
lower activation threshold and calcium mobilization upon B cell
stimulation and their autoreactive BCR repertoire (17). Age-
associated B cells (ABCs) initially had been described in mice and
described as antigen-experienced and refractory to BCR stimuli
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(18). CD11c+CD21− B cells have been described as the human
equivalent of ABCs, their frequencies increased in rheumatoid
arthritis, and correlating with patients’ age (41). Noteworthy,
in our cohort frequencies of CD11c+ cells and age did not
correlate, which is in line with a previous publication showing
no correlation between CD11chigh B cell and age of SLE patients
(1). Whether ABCs do really represent a distinct B cell lineage or
whether they rather represent a differentiation status of antigen-
experienced B cells in chronic immune reactions is debatable (4).
A limitation of the study aiming on the characterization of
checkpoint molecule expression by CD11c+ B cells is that CD21
was only included in one of two panels used, which limited the
characterization of expanded CD11c+ B cells. Other limitation is
the detection of low signals in somemarkers which should ideally
be verified by other methods. Here we describe that peripheral
CD11c+ B cells are heterogeneous in phenotype, but many
of them show reduced CD21 and CD38 expression, including
upregulated expression of a distinct pattern of checkpoint
molecules (PD-1, PDL1, CD86, CD137, CTLA4, CD226, ICOS,
and VISTA). Increased PD-1 and PD-L1 expression was
characteristic of SLE CD11c+ B cells. This suggests that CD11c+
B cell induction depends quantitively on the extent of immune
activation but can result in qualitative differences of abnormal
and likely dysregulated immune activation as exemplified
by CD11c+ B cells carrying increased PD-1 and PD-L1
in SLE.
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